Clinical Trial

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-06-24; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2026-03-26
Trial Details
NCT Number NCT07047690
Lead Sponsor Galderma R&D
Conditions Systemic Sclerosis
Enrollment 162 participants
Start Date 2026-02-20
Primary Completion 2028-05-28 (estimated)
Study Completion 2028-07-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-31